Local view for "http://purl.org/linkedpolitics/eu/plenary/2007-04-23-Speech-1-113"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20070423.17.1-113"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
"and advances in biotechnology and biomedicine lead to the development of therapies described as advanced, including gene therapy, somatic cell therapy and genetic engineering, all of which should aim at preventing disease and improving the state of human health. What has happened, however, is that experimental technology has been used to create animal-human hybrids and chimeras. It has also been applied in cloning and in experiments to change the genetic heritage of individuals. Techniques of this nature infringe ethical principles, and they are also problematic from a medical point of view. They can cause side effects as they have a negative impact on health and they lead to the commercialisation of the human body.
The situation is aggravated by the intense competition between medical and pharmaceutical concerns. It is not the first time this has led to the production of medicines or the use of D therapies with dramatic side effects.
Rejection of the amendments banning immoral practices reveals the irresponsibility of people who endanger the health and even the life of those they should be helping by condoning disregard for human dignity. At the same time, solutions at European level can be a way of forcing acceptance by those who do not agree with infringing moral principles. This amounts to a distortion of values and to putting the brakes on scientific research that complies with the principles of respect for human dignity."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples